Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients

Exclusion Criteria

• •1. Patients who have transplanted organs other than kidney
• •2. At the time of Screening
• •* Treatment with active liver disease or Liver function test(T-bilirubin, AST, ALT)is over 3 times than upper normal limit
• •* WBC\< 2,500/mm\^3, or platelet \< 75,000/mm\^3, or ANC \< 1,300/ mm\^3
• •* Protein/Creatinine ratio≥1.0(mg/mg)
• •3. Patents who had a record of taking mTOR inhibitor before 3 months
• •4. In investigator's judgement